Professor Mark Lowdell is the Professor of Cell & Tissue Therapy at University College London and an expert in Translational Cellular Immunotherapy and Regenerative Medicine.
He is also the Director of the Centre of Cell & Tissue Therapy and Biobanking / Honorary Consultant Immunologist at the Royal Free London NHS Foundation Trust.
He holds over 20 years of experience in cancer immunotherapy, particularly in the innate immune response of natural killer cells as natural anti-cancer immunotherapy agents.
Mark Lowdell established the first UK academic GMP facility which now specialises in commercialising somatic cell medicines, gene therapy and tissue engineering products. He has a clinical trial expertise and successfully acquired >£12m funding to launch a stem cell-derived trachea and larynx UK clinical trial.
Doctor Simon Waddington is an Acting Director of the Institute for Women’s Health and a Reader in Gene Transfer Technology at University College London.
He is a lead group investigator in preclinical models for gene and stem cell transfer, particularly in perinatal gene delivery for the early onset of debilitating diseases such as; neurodegenerative diseases, inherited epilepsy and metabolic diseases.
Through a collaborative alliance, he filed two patents for a gene transfer technique with application in non-invasive quantitation of signalling systems derived from diseased organs and tumours.
Doctor Davide Danovi is a Director of the Human Induced Pluripotent Stem Cells Initiative and Cell Phenotyping Programme at King’s College London.
He is a pioneer in the development of screening methods to isolate compounds which become active upon interaction with human neural stem cells. He also holds years of experience in the biotech sector where he acted as a principal scientist investigator and using innovative stem cell technology for the isolation of drugs with regenerative potential.
Ann Kramer is the CEO of The Electrospinning Company Ltd. at the University of Cambridge. A company which provides support for translating innovations into the clinic, including, design, development, regulatory and manufacturing support.
Ann holds expertise acros the business industry including research, sales, business development and M&A. Her managerial experience includes overlooking the development of genetically modified foods in fresh produce crops as well as the Head of Business development for Oxitec Ltd., COO of Immunocore Ltd. and CEO of Biosyntha Ltd.
Professor Paolo De Coppi is a Consultant Paediatric Surgeon at Great Ormond Street Hospital, Reader and Head of Stem Cells and Regenerative Medicine at the UCL Institute of Child Health in London.
His main research interests are stem cell-based and tissue engineering for the treatment of congenital malformations. He pioneered the use of amniotic fluid stem cells for therapeutic applications and later patented the discovery which opened novel approaches to correct for congenital malfunctions. He is also known for the successful transplantation of a tissue-engineered trachea in a child back in 2010. Paolo De Coppi is now developing new techniques for stem cell isolation, expansion and differentiation for use at the clinical level.
Tuesday, April 24th 2018
17:00 – 21:00 (GMT)